Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2022 - 2025)
Protagonist Therapeutics' (PTGX) quarterly Gains from Sales and Divestitures came in at $75500.0 in Q4 2025, down 76.16% year-on-year from $316748.0 in Q4 2024, and little changed quarter-over-quarter from $75500.0 in Q3 2025.
Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2022 - 2025) Analysis & Trends
Protagonist Therapeutics has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $75500.0 for Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $75500.0, down 76.16% year-over-year; the trailing twelve-month figure through Dec 2025 was $75500.0 (down 76.16% YoY), and the FY2025 annual result was $75500.0, down 76.16% from the prior year.
- Gains from Sales and Divestitures came in at $75500.0 for Q4 2025 at Protagonist Therapeutics, roughly flat from $75500.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $316748.0 in Q4 2024 to a low of $75500.0 in Q3 2025.
- The 4-year median for Gains from Sales and Divestitures is $108462.0 (2022), against an average of $170380.1.
- Across the five-year window, Gains from Sales and Divestitures jumped 171.53% in 2023 and tumbled 76.16% in 2025, its largest moves.
- Protagonist Therapeutics' Gains from Sales and Divestitures stood at $108462.0 in 2022, then jumped by 178.98% to $302582.0 in 2023, then rose by 4.68% to $316748.0 in 2024, then slumped by 76.16% to $75500.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $75500.0 (Q4 2025), $75500.0 (Q3 2025), and $316748.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Protagonist Therapeutics | 7.35 Bn | 7.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75,500.00 |
| Dec 31, 2025 | 75,500.00 |
| Sep 30, 2025 | 75,500.00 |
| Sep 30, 2025 | 75,500.00 |
| Dec 31, 2024 | 316,748.00 |
| Dec 31, 2024 | 316,748.00 |
| Dec 31, 2023 | 302,582.00 |
| Dec 31, 2023 | 302,582.00 |
| Jun 30, 2023 | 284,321.00 |
| Jun 30, 2023 | 284,321.00 |
| Mar 31, 2023 | 160,884.00 |
| Mar 31, 2023 | 160,884.00 |
| Sep 30, 2022 | 108,462.00 |
| Sep 30, 2022 | 108,462.00 |
| Jun 30, 2022 | 104,712.00 |
| Jun 30, 2022 | 104,712.00 |
| Mar 31, 2022 | 104,712.00 |
| Mar 31, 2022 | 104,712.00 |